Sanofi opts into second license with Selecta

Building on a relationship already in place, Selecta Biosciences is expanding its partnership with French pharma Sanofi to use its in-house technology platform to develop treatments for celiac disease.

The Watertown, Mass-based biotech has developed an immunotherapy platform, dubbed the Synthetic Vaccine Particle platform, or SVP, that is able...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category